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Background  28 
Concern about increasing carbapenem and piperacillin/tazobactam use led the Scottish 29 
Antimicrobial Prescribing Group (SAPG) to develop national guidance on optimal use of these agents, 30 
and to implement a quality improvement programme to assess the impact of guidance on practice. 31 
Objectives 32 
To evaluate how SAPG guidance had been implemented by health boards, assess how this translated 33 
into clinical practice, and investigate clinicians’ views and behaviours about prescribing carbapenems 34 
and alternative agents. 35 
Methods 36 
Local implementation of SAPG guidance was assessed using an online survey. A bespoke Point 37 
Prevalence Survey was used to evaluate prescribing. Clinicians’ experience of using carbapenems 38 
and alternatives was examined through semi-structured interviews. National prescribing data were 39 
analysed to assess the impact of the programme. 40 
Results 41 
There were greater local restrictions for carbapenems than for piperacillin/tazobactam. Laboratory 42 
result suppression was inconsistent between boards and carbapenem sparing antibiotics were not 43 
widely available. Compliance with local guidelines was good for meropenem but lower for 44 
piperacillin/tazobactam. Indication for use was well documented but review/stop dates were poorly 45 
documented for both antibiotics. Decisions to prescribe a carbapenem were influenced by local 46 
guidelines and specialist advice. Many clinicians lacked confidence to de-escalate treatment. Use of 47 
both antibiotics decreased during the course of the programme. 48 
 Conclusions 49 
A multi-faceted quality improvement programme was used to gather intelligence, promote 50 
behaviour change and focus interventions on use of carbapenems and piperacillin/tazobactam. Use 51 
of these antimicrobials decreased during the programme; a trend not seen in Europe outwith the 52 
UK. The programme could be generalised to other antimicrobials.   53 
Introduction 54 
Multi-drug resistant Gram negative bacteria (MDRGNB) are an escalating global problem1  and in 55 
Europe, increases in carbapenem use2 have been associated with increases in MDRGNB.3 In 2015 no 56 
European country showed a significant decrease in carbapenem use and use of 57 
piperacillin/tazobactam increased compared with 2014 data.4 Globally, carbapenem use is also 58 
increasing5 as is the incidence of carbapenem resistant Gram negative bacteria.6,7 Carbapenems and 59 
piperacillin/tazobactam have been designated as critically important antibiotics by the World Health 60 
Organisation since 20058 and in 2013, the Department of Health in England recommended 61 
protecting carbapenems and anti-pseudomonal agents to preserve their efficacy.9   62 
 63 
In Scotland, reported incidence of resistant Gram negative organisms including bacteria producing 64 
extended spectrum beta-lactamase (ESBL) were stable between 2009 and 2012, 10 although small 65 
numbers of carbapenemase-producing organisms (CPO) were increasing year on year.  66 
Piperacillin/tazobactam and carbapenem use was relatively low in Scottish hospitals in 2012: 1.9% 67 
and 1.3% respectively of total antibiotic use (defined daily dose/100 admissions), but use of both 68 
antibiotics had increased between 2009 and 2014 (51.1% and 23.1% respective increases).10     69 
 70 
In Scotland the National Health Service comprises 14 regional health boards providing hospital and 71 
community services, plus one national hospital. The national antimicrobial stewardship programme 72 
is led by the Scottish Antimicrobial Prescribing Group (SAPG), an NHS organisation hosted by 73 
Healthcare Improvement Scotland, and delivered by health board Antimicrobial Management Teams 74 
(AMTs). With the increasing threat from MDRGNB and CPO and increased use of carbapenems and 75 
piperacillin/tazobactam in Scotland, in October 2013 SAPG produced and disseminated guidance 76 
related to MDRGNB infections to AMTs (Supplementary Information). The guidance emphasised 77 
optimising use of carbapenems and piperacillin/tazobactam and considering use of carbapenem 78 
sparing antibiotics (CSA) e.g. aztreonam, temocillin, fosfomycin and pivmecillinam. The intention was 79 
for AMTs to integrate this national guidance within local policies and education programmes. This 80 
project aimed to evaluate local implementation of the national guidance and to investigate its 81 
impact on clinical practice.   82 
 83 
Materials and methods 84 
Study design 85 
The programme was overseen by a multi-professional steering group. There were three elements: a 86 
national implementation survey of health boards’ prescribing guidance and laboratory reporting 87 
practice; a bespoke Point Prevalence Survey (PPS) of carbapenems and piperacillin/tazobactam to 88 
assess their use in clinical practice; and qualitative interviews in selected boards to explore clinicians’ 89 
attitudes, strategies and barriers to the use of these antibiotics and CSAs.  Study outputs were 90 
regularly shared with SAPG members and AMTs. An interrupted time-series (ITS) analysis of 91 
antibiotic use was used to determine the impact of data sharing and clinician awareness of the 92 
programme.  93 
 94 
Survey 95 
A Survey Monkey© online tool (Supplementary Information) consisting of 49 questions was 96 
developed to seek feedback on: adoption of the SAPG MDRGNB guidance; implementation 97 
strategies; education; current local recommendations for use of carbapenems, 98 
piperacillin/tazobactam and CSAs; and local microbiology laboratory policy and practice for Gram 99 
negative isolates.  In May 2015, a link to the survey was sent to AMTs (n=15) asking them to submit 100 
one response per board.  Responses were compared to assess variation in clinical use and diagnostic 101 
microbiology laboratory practice across boards. 102 
 103 
National Point prevalence survey (PPS) 104 
A bespoke PPS focusing on meropenem (the predominant carbapenem in NHS Scotland) and 105 
piperacillin/tazobactam was undertaken in all acute Scottish hospitals (n=32) using the National 106 
Antimicrobial Stewardship Point Prevalence System (NAS-PPS) database and paper data collection 107 
forms for ward information and patient information (Supplementary Information).  PPS data coding 108 
was based on the European Society for Antimicrobial Consumption dataset (Supplementary 109 
Information) and staff were trained through online webinar sessions.   110 
The PPS was conducted during a 4-week period in September to October 2015. Information was 111 
collected on every prescription of a carbapenem or piperacillin/tazobactam for treatment of 112 
infection on the day of the survey. Prescriptions for antibiotic prophylaxis administered in the 24 113 
hours prior to the survey were also included although neither antibiotic is recommended for use as 114 
prophylaxis. 115 
Following completion of data entry, boards could analyse their own data and results were extracted 116 
by SAPG to produce summary reports for each board and a national report.  117 
 118 
Semi-structured interviews 119 
A semi-structured interview was developed to explore factors influencing prescribing of meropenem 120 
and CSAs.  The interview (Supplementary Information) consisted of five questions about prescribing, 121 
monitoring, reviewing and de-escalating meropenem; five about factors encouraging or limiting the 122 
prescription of CSAs; and an opportunity to make any other comments. Four health boards were 123 
selected based on either their good practice in use of carbapenems or use of CSAs as identified 124 
through the survey and PPS.  AMTs within each board identified a representative sample of clinicians 125 
from various specialities and grades (Supplementary Information) and each clinician was sent an 126 
invitation letter and study information.  Twenty nine one-to-one interviews were conducted by 127 
author AM between June and November 2016.  Interviews were audio recorded, transcribed 128 
verbatim and anonymised.  A thematic analysis was conducted in NVivo 11 by author AM and was 129 
validated by author SR, followed by the two researchers reaching a consensus on thematic coding. 130 
 131 
Sharing of project data 132 
Summary reports on each phase of the programme were shared via SAPG meetings, and with AMTs 133 
via email and presentations at SAPG national network events. 134 
 135 
Interrupted time-series analysis 136 
Data on carbapenems and piperacillin/tazobactam use between January 2012 and December 2016, 137 
as defined daily doses (DDDs), were obtained from the Hospital Medicines Utilisation Database 138 
(HMUD): a national database of medicines supply.  Population estimates were obtained from 139 
National Records of Scotland (NRS) and data were reported in DDDs per 100,000 population.  The 140 
time-series was split into three segments to estimate the level and trend changes in the two 141 
segments that follow each intervention compared to the preceding segment (Figure 4).  Segment 142 
one was 21 months (January 2012 to September 2013) followed by the introduction of the SAPG 143 
Guidance in October 2013 (Intervention one). Segment two was 19 months (October 2013 to April 144 
2015).   Intervention 2 was the quality improvement phase which included the AMT survey in May 145 
2015, the bespoke Point Prevalence Survey in October 2015, the sharing of reports with boards in 146 
January 2016 and the AMT event in March 2016. Segment three was 23 months (May 2015 to 147 
December 2016). A segmented regression analysis of interrupted time-series data was used to 148 
examine intervention effects11, using lag terms to adjust models for autocorrelation present in the 149 
residual terms and using heteroskedastic robust standard errors when residual terms were not 150 
homoscedastic. Intervention effect sizes are the estimated absolute and relative changes, with 95% 151 
confidence intervals12.  The absolute change is the difference between the modelled estimate at the 152 
specified post-intervention point and the modelled estimate assuming the pre-intervention trend 153 
continued.  The relative change is the absolute change as a percentage of the modelled estimate at 154 
the specified post-intervention time point.  Absolute and relative effects are calculated at one 155 
month, six months and 18 months after each intervention.  All analyses were carried out in SAS 156 
(Statistical Analysis Software 13). 157 
 158 
Ethics 159 
Caldicott Guardian approval for use of prescribing information was obtained locally within each 160 
health board.  Clinicians involved in the interviews gave written informed consent.  Formal ethical 161 
review and approval were not required because the project was a service evaluation.  The project 162 
was conducted in accordance with the Declaration of Helsinki and national and institutional 163 
standards. 164 
 165 
Results  166 
National Survey 167 
All 15 health boards responded to the survey and the key results are reported below.  Meropenem 168 
was reported to be subject to prescribing restrictions in 13 (87%)  boards, but 169 
piperacillin/tazobactam was only restricted in seven boards (47%) (Figure 1).  The most common 170 
mechanism for authorisation was through an infection specialist (microbiologist or infectious 171 
diseases physician) following a restricted antibiotics policy. These policies are not effectively 172 
monitored in many boards; however, one small board uses a highly effective coding system which 173 
also controls access to stock. Access to meropenem is mostly limited by having a 24 hour supply 174 
available via an emergency cupboard or located on specific wards.  Meropenem sensitivity reporting 175 
was automatically suppressed by laboratories in 9 (60%) of the 15 boards but 176 
piperacillin/tazobactam only in 5 boards (33%) (Figure 1). 177 
The four most commonly reported approved indications for meropenem were as second line 178 
treatment of febrile neutropenia (80% of boards), severe sepsis unresponsive to 179 
piperacillin/tazobactam (53%), infections with Pseudomonas spp. or resistant Gram-negative 180 
organism colonisation in cystic fibrosis patients (40%) and exacerbation of bronchiectasis (33%).  The 181 
following CSAs were formulary approved for use on specialist advice: fosfomycin oral (87% of 182 
boards), pivmecillinam (73%), temocillin (67%), fosfomycin intravenous (IV) (60%), aztreonam (53%).  183 
Health boards either updated local guidelines based on the SAPG MDRGNB guidance 184 
recommendations or reviewed their local guidelines and found them to be in-line with the SAPG 185 
guidance. Many boards also informed clinicians about the guidance during medical education 186 
sessions or electronically. Training on prescribing of carbapenems and piperacillin/tazobactam is 187 
integrated into routine training in most boards, mainly targeted to junior and middle grade medical 188 
staff and pharmacists.    189 
 190 
National Point prevalence survey 191 
PPS data were submitted by all 15 health boards but data from 2 small island health boards were 192 
excluded from the analysis due to delays in receiving the data. A total of 12,478 patients were sampled 193 
in 32 hospitals; all patients prescribed the study antibiotics on the day of the survey were included. 194 
Data were not collected on the total number of antibiotics prescribed or on whether the study 195 
antibiotics were prescribed as monotherapy or in combination with other antibiotics. There were 466 196 
prescriptions included: 129 of meropenem and 337 of piperacillin/tazobactam and patient 197 
demographics are shown in Figure 2A.   The majority of prescriptions were for patients over 50 years 198 
(70% of meropenem and 84% of piperacillin/tazobactam) and around 60% of prescriptions were for 199 
four or more days.  Figure 2B shows the number of prescriptions by specialty.  The most common 200 
diagnoses for meropenem use were pneumonia, intra-abdominal sepsis, febrile neutropenia or clinical 201 
sepsis, which accounted for 66% of all prescriptions.  For piperacillin/tazobactam, 70% of prescriptions 202 
were for pneumonia, intra-abdominal sepsis, febrile neutropenia or bacteraemia.  The source of 203 
infection was most often community acquired (CAI) defined as present or starting within 48 hours of 204 
admission; 58% of meropenem and 53% of piperacillin/tazobactam.  The prevalence of CAI was similar 205 
to that observed in the national PPS of HAI and antimicrobial prescribing in 2016.14 206 
The reason for the antibiotic prescription was documented in 97% of meropenem prescriptions and 207 
88% of piperacillin/tazobactam prescriptions.  Compliance with local policy was 88% for meropenem 208 
and 70% for piperacillin/tazobactam. Documentation of a review or stop date for antibiotic 209 
prescriptions was 31% for both drugs (Figure 3).  210 
To confirm that use of meropenem and piperacillin/tazobactam on the day of the PPS was typical, 211 
data were compared with the previous year’s annual use of the drugs in each health board, 212 
measured in defined daily doses (in Supplementary Information).  213 
 214 
Semi-structured interviews  215 
The main themes arising from the thematic analysis of interview data were grouped into three topic 216 
areas: initiation of a prescription, continuation of a prescription and areas for improvement. Key 217 
findings included: clinicians rely on specialists’ (Microbiologist/Infectious Disease) advice on 218 
initiation (which would be expected given their restricted status) but also relied on specialist advice 219 
on continuation/de-escalation which may indicate a lack of confidence amongst clinical teams;  220 
acknowledgement of overuse of very broad spectrum agents; a need for tools to facilitate review, 221 
de-escalation and intravenous to oral switch therapy (IVOST) to support clinicians;  lack of awareness 222 
and confidence amongst clinicians in using CSAs unless within local guidelines  or on microbiology 223 
reports or recommendation (Table 1).   224 
 225 
Interrupted time series 226 
Monthly carbapenem and piperacillin/ tazobactam DDDs per 100,000 population were plotted over 227 
the entire study period (Figure 4).  Before Intervention one carbapenems were increasing by 1 DDD 228 
per 100,000 population each month (p=0.006) from a baseline of 128.7 DDDs per 100,000 229 
population.   Intervention one was associated with an immediate decrease of 21.3 DDDs per 100,000 230 
population (p=0.001) and a change in trend of 0.58 DDDs per 100,000 population (p=0.28).  231 
Intervention two was associated with an immediate reduction of 12.3 DDDs per 100,000 population 232 
(p=0.05) and a change in trend of 2.3 DDDs per 100,000 population (p<0.001).    Before intervention 233 
one piperacillin/tazobactam was increasing by 1.4DDDs per 100,000 population each month 234 
(p<0.001) from a baseline of 188.8 DDDs per 100,000 population.  Intervention one was associated 235 
with an immediate increase of 14.9DDDs per 100,000 population (p=0.02) and a change in trend of -236 
1.5 DDDs per 100,000 population (p=0.002).  Intervention two was associated with an immediate 237 
decrease of 17.6 DDDs per 100,000 population and a change in trend of -1.6 DDDs per 100,000 238 
population (p=0.002). 239 
Segmented regression analysis showed that six months following the release of SAPG Guidance in 240 
October 2013 there was an 11.4% decrease (95% CI 19.0 to3.9) in carbapenems and a 2.5% increase 241 
(95% CI -3.2 to 8.2) in piperacillin/tazobactam.  By April 2015 the intervention effect was diminishing 242 
for carbapenem use with a smaller reduction of 6.5% (95% CI -18.4 to 5.5) while 243 
piperacillin/tazobactam use showed a decrease of 5.2% (95% CI -12.9 to 2.4).  244 
Six months after the start of the quality improvement work (Intervention two) there was a reduction 245 
in carbapenem use of 15.5% (95% CI 8.3 to 22.6) which further decreased to a 28.5% reduction (95% 246 
CI 19.3 to 37.7) by November 2016.  Piperacillin/tazobactam use continued to decrease after 247 
intervention two so that by November 2016 there was a 20.4% decrease (95% CI 12.7 to 28.1). 248 
 249 
Discussion 250 
The survey showed that the SAPG MDRGNB guidance was implemented in most boards. 251 
Meropenem is more often subject to prescribing restrictions than piperacillin/tazobactam and 252 
authorisation for use is typically through an infection specialist.  There is inconsistency in the 253 
approach of microbiology laboratories towards antimicrobial stewardship nationally and the 254 
suppression and release of antimicrobials occurs via a variety of mechanisms. There is scope and an 255 
appetite amongst laboratory clinicians and scientists for standardisation, which is being progressed 256 
via collaboration of SAPG with the Scottish Microbiology and Virology Network. Most boards only 257 
use carbapenem sparing antibiotics (CSAs) for specific indications on specialist advice and only two 258 
boards have embraced their use through inclusion in local antibiotic guidance. Barriers to use of 259 
CSAs are additional costs compared with generic meropenem and issues with stock shortages. 260 
Older CSAs have a limited evidence base and further studies are required to demonstrate efficacy in 261 
the current resistance landscape15. However, new agents are coming to market e.g. 262 
ceftolozane/tazobactam and may offer another alternative to carbapenems.  263 
 264 
SAPG utilises periodic on-line surveys of AMTs to obtain feedback on implementation of national 265 
stewardship initiatives, barriers to implementation and suggestions for future improvement work. 266 
This provides an essential evaluation element to the stewardship programme and also informs 267 
future planning. The survey on the use of carbapenems and piperacillin/tazobactam was the fourth 268 
AMT survey and focused on implementation of national guidance which was subsequently reviewed 269 
and updated in 201616 to reflect the findings of this work and additional evidence from the 270 
literature. A multi-pronged approach to hospital stewardship is highlighted in the recent Cochrane 271 
review17 so it is encouraging that our survey confirmed that implementation of local guidance was 272 
supported by education for key clinical staff. Extension of stewardship training beyond junior and 273 
middle grade doctors to include consultants may be helpful to ensure leadership for stewardship 274 
and drive behaviour change. Antimicrobial pharmacists are also a key source of specialist advice for 275 
clinical teams in Scotland and training for nursing staff is also important with their evolving role in 276 
stewardship.18 277 
Additional to the reported results, the survey confirmed that most boards monitor consumption of 278 
carbapenems and piperacillin/tazobactam quarterly as recommended in national surveillance 279 
guidance.19 Consumption reports are shared at AMT meetings and, in many boards, with Infection 280 
Prevention and Control Committees, supporting an integrated approach to stewardship. Awareness 281 
of consumption trends is crucial to improving prescribing practice and to assessing the impact of 282 
interventions.20  283 
 284 
The survey described the local processes to support appropriate use of carbapenems and 285 
piperacillin/tazobactam but from a stewardship perspective it is important to understand how this 286 
translates into prescribing practice which was the key aim of the PPS. National PPS are used 287 
throughout Europe21 to evaluate the prevalence of Healthcare Associated Infection and 288 
antimicrobial prescribing and have provided SAPG with quantitative and qualitative data to inform 289 
on areas for improvement.14 290 
In the bespoke PPS, the lack of good documentation for piperacillin/tazobactam use may reflect its 291 
place as the ‘go to’ antibiotic for severe infection. The recent worldwide shortage of 292 
piperacillin/tazobactam has gone some way to changing this, with national agreement via SAPG in 293 
May 2017 to reserve piperacillin/tazobactam for treatment of suspected neutropenic sepsis and as 294 
directed by infection specialists for other specific infections. Further analysis of the PPS data showed 295 
that carbapenem use was below 2% of all antibiotics in all boards and less than 1% in many. 296 
Piperacillin/tazobactam use varied from 1% to over 6% possibly reflecting different controls over use 297 
rather than clinical justification. Another key finding from the PPS was that over half of patients had 298 
received antibiotics for over 72 hours and about one third of these patients had no documented 299 
review or stop date recorded in their medical notes. These findings are informing SAPG work on 300 
antibiotic review to support clinical teams through education and quality improvement tools to 301 
optimise prescribing practice. 302 
The interviews with clinicians suggest that many prescribers are not confident in reviewing 303 
intravenous antimicrobial therapy in patients with severe infection where oral switch options may 304 
be unclear and there is a perceived need for additional input from infection specialists. Although 305 
carbapenems and to some extent piperacillin/tazobactam are often prescribed following advice from 306 
microbiology, there is a perception that there is a relative lack of follow-up discussion between the 307 
clinical team and microbiology. In addition, variance in the suppression or release of full 308 
microbiology reports can lead to patients remaining on the original treatment despite clinical 309 
improvement and lack of positive microbiology. This can be addressed through Antimicrobial Ward 310 
Rounds22 but these are unlikely to capture all patients prescribed these agents in a timely manner. 311 
Therefore there appears to be a learning need to upskill prescribers as well as developing systems to 312 
more easily identify prescription of these antibiotics to facilitate review. Evidence from the 313 
interviews clearly identified that there was a need for a whole system approach which includes the 314 
organisational systems and local policies (the environment), improved communication within the 315 
multidisciplinary team (the clinicians) and better availability and use of CSAs (the medicines).   We 316 
acknowledge that selection bias is a limitation of this phase of the programme since we involved 317 
clinicians in only 4 of the 15 health boards selected based on local good practice. However they 318 
represented boards of varying size, a mix of teaching hospitals and district generals and urban and 319 
rural populations. 320 
During the course of this two-year improvement programme, national use of carbapenems and 321 
piperacillin/tazobactam have decreased although there is some variation between boards in terms 322 
of reduced consumption. Some of this change can be attributed to the various elements of the 323 
programme as illustrated by the interrupted time series analysis. The impact on consumption may 324 
be a Hawthorn effect, but measurement and in-depth study of organisational systems coupled with 325 
continuous feedback of findings through multiple forums appears to be supportive in reducing use. 326 
During the last 2 years use of CSAs has increased in some health boards, particularly aztreonam and 327 
temocillin, and reassuringly there has been no upward trend in use of 3rd generation cephalosporins 328 
or fluoroquinolones in Scottish hospitals (data not shown). 329 
 330 
SAPG had previously completed a quality improvement programme for gentamicin and 331 
vancomycin23 and this work on carbapenems used a similar approach. Such programmes utilise 332 
several methods to gain intelligence about clinical practice and target areas for improvement. SAPG 333 
has an extremely well engaged network of local AMTs which support our work, facilitating a 334 
resource-light approach. The study findings are continuing to shape the direction of SAPG quality 335 
improvement initiatives, including:  336 
 Highlighting the need to feature CSAs in local guidelines and ensure availability of stock.  337 
 Working with microbiology colleagues to develop a standardised approach to antimicrobial 338 
susceptibility testing and reporting. 339 
 Encouraging boards to develop local systems to identify initiation of a carbapenem to enable a 340 
formal review process by the attending clinical team and/or infection specialists. 341 
 Developing a national standard and supporting toolkit for review of IV antibiotic therapy.  342 
This work demonstrates how a multi-faceted quality improvement programme can be used to gather 343 
intelligence, promote behaviour change and focus interventions to optimise use of very broad 344 
spectrum antibiotics. Recent national trends in use of these antibiotics continue to show a 345 
downward trend and rates are significantly lower than in other UK nations24. Comparison with other 346 
European countries4 suggests Scotland is ‘bucking the trend’ of stable or increasing rates of 347 
carbapenem and piperacillin/tazobactam use.  We consider this three-part improvement project will 348 
be of interest to stewardship colleagues as it can be applied to other antimicrobials to investigate 349 
and inform safe and effective clinical practice. 350 
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Initiation phase 
Factors influencing prescribing of meropenem and CSAs: 
 Local guidelines and policies 
 Prescribers seeking advice or laboratory results 
 Patient-related factors 
 Carbapenem-sparing agent prescribing levers 
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Areas for improvement 
Factors to target identified by clinicians: 
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 Audit and feedback to prescribers on their use 
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